Evidence map›Paper›PMID 42207440›Full record

ArticleIn vitro cellular & developmental biology. Animal2026

ALKBH4 confers ferroptosis resistance and drives tumorigenesis via dysregulation of GPX4 in breast cancer cells.

Mengyuan Wu, Fanlong Meng, Meiqi Xu, Feng Pei, Yakun Luo

Abstract read
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mengyuan Wu *NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, China.
Fanlong Meng *NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, China.
Meiqi Xu *NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, China.
Feng PeiNHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, China.
Yakun LuoNHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, China. luoyankun@hrbmu.edu.cn.

Funding

National Key Research and Development Program of China 2022YFA1205704National Natural Science Foundation of China 82503606Natural Science Foundation of Heilongjiang Province YQ2023H015Research Fund of the Fourth Affiliated Hospital of Harbin Medical University HYDSYRCYJ02
6 · The paper itself

Abstract

Breast cancer (BC) remains a predominant source of cancer-related fatalities among women globally. While the AlkB homolog family member ALKBH4 has been implicated in cancer, its role and mechanism in BC are unknown. Its role within BC and its correlation with ferroptosis-a type of iron-mediated regulated cell death, were examined in this work. Data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and immunohistochemistry (IHC) analyses indicate ALKBH4 overexpression in BC, further associating its high expression levels with unfavorable clinical outcomes. Functional experiments in BC cells demonstrated that ALKBH4 knockdown exerted inhibitory effects on proliferation, migration, and invasion. Concurrently, it promoted apoptosis. Transcriptomic and biochemical investigations revealed that knocking down ALKBH4 sets off a ferroptotic cascade, with telltale signs including heightened levels of malondialdehyde (MDA) and ferrous iron (Fe

Indexed as

AlkB EnzymesBreast NeoplasmsCarcinogenesisFerroptosisPhospholipid Hydroperoxide Glutathione PeroxidaseAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansReactive Oxygen SpeciesAlkB EnzymesPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen SpeciesALKBH4Breast cancerFerroptosisGPX4Lipid peroxidationTherapeutic target

Identifiers

PMID42207440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.